Full Press Release Details
Novato, CA, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a
biopharmaceutical company focused on the development of novel
products for rare and ultra-rare diseases, today announced that
Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer,
will be presenting at the Leerink Partners Rare Disease Roundtable
on October 1, 2014 at 9:40am ET at the Le Parker Meridien Hotel in
The live and archived webcast of the company presentation will
be accessible from the company's website at http://ir.ultragenyx.com/events.cfm.
The replay of the webcast will be available for 60 days.
Ultragenyx is a clinical-stage biopharmaceutical company
committed to bringing to market novel products for the treatment of
rare and ultra-rare diseases, with a focus on serious, debilitating
genetic diseases. Founded in 2010, the company has rapidly built a
diverse portfolio of product candidates with the potential to
address diseases for which the unmet medical need is high, the
biology for treatment is clear, and for which there are no approved
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx's strategy is predicated upon time and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at www.ultragenyx.com.